Amneal Pharmaceuticals, Inc.
AMRX · XNASCIK 1723128fmd_10973ZSNMKMETA1EWC90F7NBMRManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2016 to Sep 30, 2026, 40 periods
Latest annual · FY2025
Millions- Total revenues
- 3,019
- Gross profit
- 1,113
- Operating income
- 394
- Net income
- 72
- Free cash flow
- 270
Latest quarter · Q3 FY2026
Millions- Total revenues
- 863
- Gross profit
- 334
- Operating income
- 95
- Net income
- (22)
- Free cash flow
- 67
Daily close · AMRXIEX trades only
Nov 13, 2025 to Nov 11, 2026 · 250 sessions21.72 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- +10.9%
- Revenue, 5 yearsFY2020 to FY2025
- +8.7%
- Net income, 5 yearsFY2020 to FY2025
- +1.2%
Amneal Pharmaceuticals, Inc. (AMRX) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $3 billion | $2.8 billion | +8% | 10-K 2026-02-27 · proof |
| Gross profit | $1.1 billion | $1 billion | +9.1% | 10-K 2026-02-27 · proof |
| Operating income | $394.1 million | $249.3 million | +58.1% | 10-K 2026-02-27 · proof |
| Net income | $72.1 million | -$116.9 million | 10-K 2026-02-27 · proof | |
| Cash from operating activities | $340 million | $295.1 million | +15.2% | 10-K 2026-02-27 · proof |
| Free cash flow | $269.9 million | $243.2 million | +11% | 10-K 2026-02-27 · proof |
| Total assets | $3.7 billion | $3.5 billion | +5.1% | 10-K 2026-02-27 · proof |
| Total liabilities | $3.7 billion | $3.5 billion | +3.6% | 10-K 2026-02-27 · proof |
| Cash and cash equivalents | $282 million | $110.6 million | +155.1% | 10-K 2026-02-27 · proof |
| Total debt | $2.6 billion | $2.4 billion | +7.8% | 10-K 2026-02-27 · proof |
- What was Amneal Pharmaceuticals, Inc. (AMRX)'s revenue in fiscal 2025?
- Amneal Pharmaceuticals, Inc. (AMRX) reported revenue of $3 billion for fiscal 2025 (the year ended Dec 31, 2025), against $2.8 billion the year before (+8%). Source: the 10-K filed with the SEC on Feb 27, 2026. SEC
- What was Amneal Pharmaceuticals, Inc. (AMRX)'s gross profit in fiscal 2025?
- Amneal Pharmaceuticals, Inc. (AMRX) reported gross profit of $1.1 billion for fiscal 2025 (the year ended Dec 31, 2025), against $1 billion the year before (+9.1%). Source: the 10-K filed with the SEC on Feb 27, 2026. SEC
- What was Amneal Pharmaceuticals, Inc. (AMRX)'s operating income in fiscal 2025?
- Amneal Pharmaceuticals, Inc. (AMRX) reported operating income of $394.1 million for fiscal 2025 (the year ended Dec 31, 2025), against $249.3 million the year before (+58.1%). Source: the 10-K filed with the SEC on Feb 27, 2026. SEC
- What was Amneal Pharmaceuticals, Inc. (AMRX)'s net income in fiscal 2025?
- Amneal Pharmaceuticals, Inc. (AMRX) reported net income of $72.1 million for fiscal 2025 (the year ended Dec 31, 2025), against -$116.9 million the year before. Source: the 10-K filed with the SEC on Feb 27, 2026. SEC
- What was Amneal Pharmaceuticals, Inc. (AMRX)'s cash from operating activities in fiscal 2025?
- Amneal Pharmaceuticals, Inc. (AMRX) reported cash from operating activities of $340 million for fiscal 2025 (the year ended Dec 31, 2025), against $295.1 million the year before (+15.2%). Source: the 10-K filed with the SEC on Feb 27, 2026. SEC
- What was Amneal Pharmaceuticals, Inc. (AMRX)'s free cash flow in fiscal 2025?
- Amneal Pharmaceuticals, Inc. (AMRX) reported free cash flow of $269.9 million for fiscal 2025 (the year ended Dec 31, 2025), against $243.2 million the year before (+11%). Source: the 10-K filed with the SEC on Feb 27, 2026. SEC
- What are Amneal Pharmaceuticals, Inc. (AMRX)'s total assets?
- As of Dec 31, 2025, Amneal Pharmaceuticals, Inc. (AMRX) reported total assets of $3.7 billion, against $3.5 billion a year earlier (+5.1%). Source: the 10-K filed with the SEC on Feb 27, 2026. SEC
- What are Amneal Pharmaceuticals, Inc. (AMRX)'s total liabilities?
- As of Dec 31, 2025, Amneal Pharmaceuticals, Inc. (AMRX) reported total liabilities of $3.7 billion, against $3.5 billion a year earlier (+3.6%). Source: the 10-K filed with the SEC on Feb 27, 2026. SEC
- What are Amneal Pharmaceuticals, Inc. (AMRX)'s cash and cash equivalents?
- As of Dec 31, 2025, Amneal Pharmaceuticals, Inc. (AMRX) reported cash and cash equivalents of $282 million, against $110.6 million a year earlier (+155.1%). Source: the 10-K filed with the SEC on Feb 27, 2026. SEC
- What is Amneal Pharmaceuticals, Inc. (AMRX)'s total debt?
- As of Dec 31, 2025, Amneal Pharmaceuticals, Inc. (AMRX) reported total debt of $2.6 billion, against $2.4 billion a year earlier (+7.8%). Source: the 10-K filed with the SEC on Feb 27, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:AMRX&period_type=annual&limit=5"Information only, not investment advice.